<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775121</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01882-53</org_study_id>
    <secondary_id>2018/2774</secondary_id>
    <nct_id>NCT04775121</nct_id>
  </id_info>
  <brief_title>Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia</brief_title>
  <acronym>MONOLIFE</acronym>
  <official_title>Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the rate of bone marrow release and the lifespan of classical monocytes in the&#xD;
      peripheral blood of patients with a chronic myelomonocytic leukemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Deuterium glucose ingestion on a 3-hour period to label rapidly proliferating cells, followed by sequential collection of sorted classical monocytes on a 30-day period</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone marrow release</measure>
    <time_frame>up to 30 days</time_frame>
    <description>To measure bone marrow release in the peripheral blood of patients with a chronic myelomonocytic leukemia and age-matched healthy volunteers</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Deuterium Glucose</intervention_name>
    <description>Oral administration of 20 g Deuterium Glucose on a 3-hour</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients with CMML:&#xD;
&#xD;
          -  Adult aged 18 years or over&#xD;
&#xD;
          -  CMML diagnosis according to the WHO 2016 criteria&#xD;
&#xD;
          -  Untreated patient or patient who did not receive a cytoreductive drug such as&#xD;
             Hydroxyurea or an Erythropoiesis Stimulating Agent (ESA), or a growth factor, or&#xD;
             Eltrombopag within the last 2 months or patient who did not receive a hypomethylating&#xD;
             drug (Azacytidine or Decitabine) within the last 3 months&#xD;
&#xD;
          -  Affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
          -  Able and willing (in the Investigator's opinion) to comply with all study requirements&#xD;
&#xD;
          -  Able to comprehend the Information Sheet and willing to give written informed&#xD;
             consentent prior to any protocol-specific procedures performed&#xD;
&#xD;
          -  Willing to allow the Investigator to review data from the hospital medical records&#xD;
&#xD;
          -  For women of child-bearing age only, willingness to practice continuous effective&#xD;
             contraception during the study. Women of childbearing potential must have a negative&#xD;
             urine β-HCG pregnancy test within 15 days prior to the first administration of&#xD;
             deuterium-labeled glucose. Sexually active male patients must agree to use condoms&#xD;
             during the study. Also, it is recommended their women of childbearing potential&#xD;
             partner use an effective method of contraception during the same period&#xD;
&#xD;
        Exclusion Criteria for patients with CMML:&#xD;
&#xD;
          -  Severe anemia (Hb &lt; 10 g/dL)&#xD;
&#xD;
          -  Severe thrombocytopenia (Platelets &lt; 50 G/L)&#xD;
&#xD;
          -  Transfusion dependency&#xD;
&#xD;
          -  Active or recent infection or febrile illness (&lt;1 month)&#xD;
&#xD;
          -  Currently active inflammatory or autoimmune condition&#xD;
&#xD;
          -  Current systemic steroid therapy or other immunomodulatory drugs&#xD;
&#xD;
          -  Recent vaccination (&lt; 1 month)&#xD;
&#xD;
          -  Recent surgery (&lt; 1 month)&#xD;
&#xD;
          -  Active malignant disease&#xD;
&#xD;
          -  Renal disease (serum creatinine&gt; 300umol/L)&#xD;
&#xD;
          -  Hepatic disease (transaminase levels &gt;3x ULN)&#xD;
&#xD;
          -  Severe or unstable cardiovascular disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Other current active medical condition which the Investigator considers a risk for&#xD;
             entry in the study&#xD;
&#xD;
          -  Simultaneous participation in another concurrent research study that conflicts e.g. if&#xD;
             it also involves blood sampling&#xD;
&#xD;
          -  Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
&#xD;
        Inclusion Criteria of age-matched healthy donors:&#xD;
&#xD;
          -  Volunteers aged 55 years or over&#xD;
&#xD;
          -  Able and willing to comply with all study requirements&#xD;
&#xD;
          -  Able to comprehend the Information Sheet and willing to give written informed consent&#xD;
             prior to any protocol-specific procedures performed&#xD;
&#xD;
          -  For women of child-bearing age only, willingness to practice continuous effective&#xD;
             contraception during the study. Women of childbearing potential must have a negative&#xD;
             urine β-HCG pregnancy test within 15 days prior to the first administration of&#xD;
             deuterium-labeled glucose. Sexually active male patients must agree to use condoms&#xD;
             during the study. Also, it is recommended their women of childbearing potential&#xD;
             partner use an effective method of contraception during the same period.&#xD;
&#xD;
        Exclusion Criteria of age-matched healthy donors:&#xD;
&#xD;
          -  Current treatment for any type of disease&#xD;
&#xD;
          -  Current active medical condition&#xD;
&#xD;
          -  Recent vaccination (&lt; 1 month)&#xD;
&#xD;
          -  Recent surgery (&lt; 1 month)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Simultaneous participation in another concurrent research study that conflicts e.g. if&#xD;
             it also involves blood sampling&#xD;
&#xD;
          -  Subject under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric SOLARY, MD-PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.solary@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thibaud MOTREFF</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>thibaud.motreff@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric SOLARY, MD-PhD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.solary@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thibaud MOTREFF</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>thibaud.motreff@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

